COSMO PHARM N overview

Cosmo Pharmaceuticals N.V. / Key word(s): Bond Cosmo confirms full redemption in cash of €175m Convertible Bonds 06.12.2023 / 06:00 GMT/BST Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash. Upcoming Calendar of Events Preliminary Results 2023 February 15, 2024 Full Year 2023 Results and Annual Report 2023 March 21,...

Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Admission Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA) 10.10.2023 / 06:00 GMT/BST Submission to EMA is supported and based on the efficacy and safety evidence gathered in two identical, randomized, placebo-controlled phase III clinical trials enrolling >1,400 patients with acne vulgaris. The trials were successful and Winlevi® met the three co-primary endpoints, demonstrating treatment success in...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries 02.10.2023 / 06:00 GMT/BST Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the signing of a license agreement for Winlevi ® (clascoterone) cream 1% in the Middle East and North Africa...

Cosmo Pharmaceuticals N.V. / Key word(s): Contract Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa 27-Sep-2023 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Cassiopea, the subsidiary of Cosmo, will be responsible for Centralized Marketing Authorization at European Medicines Agency, while Glenmark will undertake registration of...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions 04.09.2023 / 06:00 GMT/BST Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd. (“Adalvo”) today announced the signing of a license and supply agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA)...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BST Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries. Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved...

Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results Cosmo presents strong H1 2023 operational and financial results 26-Jul-2023 / 05:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Reaffirmation of FY 2023 guidance of total revenues in the range of €110 million - €120 million and an operating profit in the range of €25 million - €35 million...

Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023 05.07.2023 / 06:15 GMT/BST Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wednesday, 26 July 2023 at 07:00 am CEST . Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation which will follow at...